US Patent

US11331315 — Aripiprazole oral soluble film

Formulation · Assigned to Xiamen LP Pharmaceutical Co Ltd · Expires 2040-11-03 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an aripiprazole oral soluble film that contains 10-60% aripiprazole and 30-95% film-forming materials.

USPTO Abstract

The present invention is directed to an aripiprazole oral soluble film and a preparation method thereof. The aripiprazole oral soluble film comprises 10-60% w/w of aripiprazole in a crystalline state and 30-95% w/w of one or more film-forming materials, wherein 90% of the aripiprazole particles have a size of ≤14.3 μm and are uniformly blended in the film without visible undispersed particles. The aripiprazole oral soluble film has excellent bioavailability, uniformity, stability, and palatability. The oral soluble film preparation is prepared by first grinding aripiprazole particles to have desired small particle sizes, then blending the aripiprazole particles with film forming materials in an aqueous solution to a uniform suspension, defoaming the suspension, and coating the suspension on a substrate and drying it to form a film.

Drugs covered by this patent

Patent Metadata

Patent number
US11331315
Jurisdiction
US
Classification
Formulation
Expires
2040-11-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Xiamen LP Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.